TP53 and hepatocellular carcinoma: Although aldometanib does not exert cytotoxicity toward cells, we show that aldometanib drastically inhibits the growth and development of HCC in diethylnitrosamine (DEN)-treated and high-fat diet (HFD)-fed mice (DEN-HFD mice), mice with hepatic knockout of Trp53 coupled with overexpression of Myc (MYC;Trp53−/− HCC39), and orthotopic allografts established by HCC cell lines.